GMABGenmab A/S

$33.75

$21.0852 weeks$35.34

Price

$33.75+49%1Y

1M+16%1Y+49%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value67

Quality89

Momentum54

Growth73

Strongest Quality, weakest Momentum · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are an international biotechnology company with a pipeline of novel antibody-based products and product candidates designed to address medical needs and improve treatment outcomes for patients with cancer and other serious diseases. Our goal in building our pipeline is to bring medicines to market ourselves in geographic areas where we believe we will be able to maximize their value and make a meaningful impact on the treatment landscape.

In the company’s own words · 20-F filed Feb 17, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$15.51B

1Y Return+49%

5Y Return-25%

Genmab A/S (GMAB) reported revenue of DKK 12.0B in H2 2024 (quarter ended December 31, 2024), up 187% from the same quarter a year earlier. That came with a gross margin of 95% and net income of DKK 5.11B (43% of revenue). For the full year FY2024, revenue was DKK 21.5B (+31% year on year) and net income DKK 7.84B.

Raw charts

6 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #31 of 145 by Smart Score

Jazz Pharmaceuticals plc

BBIO+0.48%

BridgeBio Pharma, Inc.

Ionis Pharmaceuticals, Inc.